Clinical trial shows by 2030 that GLP-1 receptor agonists significantly reduce osteoarthritis symptoms
Gezondheid en geneeskundeOne-OffManifold MarketsGeslotenGeen KYCGeverifieerde afwikkelingsgegevensGoed gekalibreerdDeze markt is beslist: Yes (77.7%)
Afgewikkeld: 3 okt 2026, 01:08
Door provider geverifieerde afwikkeling
CoinRithm heeft provider-onderbouwd bewijs voor de winnaar en afwikkelingstijd van deze markt.
Winnende Uitkomst
Yes
Op 7 dagen afstand
—
Op 24 uur afstand
78%
ConsensusWaarschuwing datakwaliteitVerouderde gegevens
Gegevens van 3 okt 2026, 07:01 UTC · beleid pm-quality-4
Waarschijnlijkheidstijdlijn
Yes77.7%
No22.299999999999997%
Gewonnen
Verloren
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 24 months?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsBy 2030, will LLMs have a bigger impact on the economy than GLP-1 receptor agents?
Manifold MarketsWill a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
Manifold MarketsWhen will the FDA reclassify BPC-157 to Category 1?
KalshiHantavirus pandemic in 2026?
PolymarketRegels
Resolution criteria
- This market will resolve to "Yes" if, by December 31, 2030, a peer-reviewed clinical trial demonstrates that GLP-1 receptor agonists significantly reduce osteoarthritis symptoms in humans.
- The trial must be published in a reputable medical journal and show statistically significant improvements in osteoarthritis symptoms compared to a control group.
- The primary outcome measures should include validated assessments of pain, physical function, and/or structural changes in the affected joints.
- If no such study is published by the specified date, the market will resolve to "No".
- If such a study sets out to investigate this and finds no significant reduction of such symptoms before market end date the market also resolves "No".